Atrium Therapeutics Ownership | Who Owns Atrium Therapeutics?
Atrium Therapeutics Ownership Summary
Atrium Therapeutics is owned by 9.78% institutional investors, 4.27% insiders, and 85.95% retail investors. Vanguard group is the largest institutional shareholder, holding 9.90% of RNA shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 4.27% of its assets in Atrium Therapeutics shares.
RNA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Atrium Therapeutics | 9.78% | 4.27% | 85.95% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vanguard group | 13.65M | 9.90% | $984.52M |
| Blackrock | 8.62M | 9.89% | $352.23M |
| Rtw investments, lp | 11.37M | 8.77% | $495.51M |
| Sessa capital im | 551.39K | 3.22% | $7.37M |
| Norges bank | 3.05M | 2.21% | $219.74M |
| Polar capital | 2.80M | 2.16% | $121.85M |
| Boxer capital | 1.73M | 1.98% | $70.56M |
| Cantor fitzgerald, l. p. | 235.64K | 1.38% | $3.15M |
| Arbiter partners capital management | 230.00K | 1.34% | $3.08M |
| T. rowe price investment management | 1.40M | 1.08% | $61.08M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Rtw investments, lp | 11.37M | 6.11% | $495.51M |
| Bioimpact capital | 760.02K | 5.42% | $33.11M |
| Boxer capital | 1.73M | 3.72% | $70.56M |
| Catalio capital management, lp | 263.26K | 2.12% | $11.47M |
| Arbiter partners capital management | 230.00K | 1.76% | $3.08M |
| Ecor1 capital | 765.00K | 1.60% | $33.33M |
| Stempoint capital lp | 114.05K | 1.00% | $4.97M |
| Eversept partners, lp | 302.91K | 0.91% | $13.20M |
| Cormorant asset management, lp | 300.00K | 0.90% | $13.07M |
| Palo alto investors lp | 109.83K | 0.89% | $4.79M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Norges bank | 3.05M | 0.02% | 3.05M |
| Blackrock | 8.62M | 0.01% | 2.46M |
| Rtw investments, lp | 11.37M | 6.11% | 1.75M |
| Polar capital | 2.80M | 0.59% | 1.03M |
| Suvretta capital management | 750.00K | 0.84% | 750.00K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | - | - | -12.85M |
| Ra capital management | - | - | -8.64M |
| Janus henderson group | - | - | -6.94M |
| Balyasny asset management | - | - | -6.04M |
| Pentwater capital management lp | - | - | -6.03M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Norges bank | 3.05M | 0.02% | 3.05M | $219.74M |
| Suvretta capital management | 750.00K | 0.84% | 750.00K | $32.68M |
| Artal group | 655.55K | 0.68% | 655.55K | $26.78M |
| Baker bros. advisors lp | 625.00K | 0.20% | 625.00K | $27.23M |
| Sessa capital im | 551.39K | 0.13% | 551.39K | $7.37M |
Sold Out
| Holder | Change |
|---|---|
| Sjs investment consulting | -1.00 |
| Mai capital management | -1.00 |
| Massmutual trust co fsb/adv | -1.00 |
| American capital advisory | -1.00 |
| Dinuzzo private wealth | -1.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 53 | -85.40% | 1,674,179 | -98.81% | 9 | 0.00% | 13 | -94.20% | 38 | -56.32% |
| Dec 31, 2025 | 226 | -23.39% | 67,965,698 | -57.78% | 49 | 0.32% | 133 | -34.48% | 57 | 1.79% |
| Sep 30, 2025 | 164 | -23.72% | 64,667,711 | -52.44% | 49 | 0.45% | 117 | 6.36% | 37 | -51.32% |
| Jun 30, 2025 | 214 | -6.96% | 135,949,346 | 3.28% | 104 | 1.01% | 109 | -16.15% | 76 | 16.92% |
| Mar 31, 2025 | 231 | -7.23% | 133,386,370 | 4.47% | 103 | 0.96% | 130 | -7.14% | 65 | -12.16% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 5.49M | 4.27% | 109.14K |
| Fidelity Growth Compy Commingled Pl O | 4.86M | 4.11% | -69.00K |
| US Small-Cap Growth II Equity Comp | 3.95M | 3.28% | -484.27K |
| Fidelity Growth Company Fund | 3.99M | 3.10% | 77.74K |
| Vanguard US Total Market Shares ETF | 3.53M | 2.93% | 3.12K |
| Vanguard Total Stock Mkt Idx Inv | 4.54M | 2.92% | 10.44K |
| T. Rowe Price New Horizons | 3.54M | 2.75% | -414.46K |
| Vanguard Health Care Inv | 2.83M | 2.35% | -196.40K |
| Vanguard Small Cap Index | 3.25M | 2.09% | 3.86K |
| iShares Russell 2000 ETF | 2.77M | 1.79% | 2.77M |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jan 21, 2026 | Hughes Steven George | Chief Medical Officer | Sell | $208.51K |
| Jan 21, 2026 | Hughes Steven George | Chief Medical Officer | Sell | $146.13K |
| Jan 21, 2026 | Boyce Sarah | President and CEO | Sell | $463.25K |
| Jan 21, 2026 | Boyce Sarah | President and CEO | Sell | $579.09K |
| Jan 21, 2026 | Flanagan W. Michael | Chief Scientific Officer | Sell | $288.06K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 18 |
| 2025 Q4 | - | 3 |
| 2025 Q3 | - | 23 |
| 2025 Q2 | - | 5 |
| 2025 Q1 | - | 23 |
RNA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools